The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To evaluate the cost–effectiveness of oral semaglutide+metformin versus empagliflozin+metformin in people with Type 2 diabetes uncontrolled on msetformin alone. Materials and methods: The IQVIA Core Diabetes Model was populated with efficacy data from a head-to-head study between oral semaglutide+metformin and empagliflozin+metformin. Danish costs and quality-of-life data were sourced from literature. Price per day was Danish Krone (DKK) 25.53 for oral semaglutide and DKK11.40 for empagliflozin. Discounting was fixed at 4%. Scenario and sensitivity analyses were performed. Results: Over a lifetime, Core Diabetes Model projected 8.78 and 8.75 quality-adjusted life-years and a total cost of DKK 447,633 and DKK 387,786, thereby generating an incremental cost–effectiveness ratio of DKK 1,930,548 for oral semaglutide+metformin versus empagliflozin+metformin. Scenario and sensitivity analyses showed the robustness of the outcomes. Duration of treatment with oral semaglutide is the key driver of the analyses. Conclusion: Oral semaglutide+metformin seems not cost effective versus empagliflozin+metformin in patients uncontrolled on metformin in Denmark.
Supplementary Material
File (supplementary material.docx)
- Download
- 139.54 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Sundhedsdatastyrelsen. Udvalgte kroniske sygdomme og svære psykiske lidelser (Selected chronic diseases and severe mental disorders (2021). www.esundhed.dk/Registre/Register-for-udvalgte-kroniske-sygdomme
2.
Statens Institut for Folkesundhed. Sygdomsudviklingen i Danmark fremskrevet til 2030 (2017). www.sdu.dk/sif/-/media/images/sif/sidste_chance/sif/udgivelser/2017/sygdomsudviklingen_i_danmark_fremskrevet_til_2030.pdf
3.
Danish Society of Cardiology and Danish Society of Endocrinology. Diabetes and cardiovascular disease (2021). https://nbv.cardio.dk/diabetes
• These guidelines are the basis of the choice of next-line therapies.
4.
Sortsø C, Green A, Jensen PB, Emneus M. Societal costs of diabetes mellitus in Denmark. Diabet. Med. 33(7), 877–885 (2016).
5.
Dansk Endokrinologisk Selskab. NBV: behandling og kontrol af Type 2 Diabetes. www.endocrinology.dk/index.php/nbvhovedmenu/1-diabetes-mellitus/nbv-endokrinologi-behandling-og-kontrol-af-type-2-diabetes-t2d-diabetes-arskontrol-nyopdaget-diabetes-2-peroral-behandling-insulin-behandling-kolesterolbehandling-blodtryksbehandling-glp1-og-dpp4
• These guidelines are the basis of the choice of next-line therapy.
6.
American Diabetes Association. Standards of medical care in diabetes 2018. Diabetes Care 41(Suppl. 1), S1–S159 (2018).
7.
Buse JB, Wexler DJ, Tsapas A et al. 2019 update to: management of hyperglycaemia in Type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63(2), 221–228 (2020).
• These guidelines are the basis of the choice of next-line therapy.
8.
Food and Drug Administration. Guidance for industry–evaluating cardiovascular risk in new antidiabetic therapies to treat Type 2 diabetes. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, DC, USA (2008). www.fda.gov/media/71297/download
9.
Schnell O, Rydén L, Standl E, Ceriello A. Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc. Diabetol. 15(1), 139 (2016).
10.
Schnell O, Rydén L, Standl E, Ceriello A. Updates on cardiovascular outcome trials in diabetes. Cardiovasc. Diabetol. 16(1), 128 (2017).
11.
Husain M, Birkenfeld AL, Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 381(9), 841–851 (2019).
12.
Clinicaltrials.Gov. Semaglutide cardiovascular outcomes trial in patients with Type 2 diabetes (2020). https://clinicaltrials.gov/ct2/show/NCT03914326?term=oral+semaglutide&type=Intr&fund=2&draw=5&rank=35
13.
Rodbard HW, Rosenstock J, Canani LH et al. Oral semaglutide versus empagliflozin in patients with Type 2 diabetes uncontrolled on metformin: the PIONEER 2 Trial. Diabetes Care 42(12), 2272–2281 (2019).
•• Basis of efficacy of the drugs under study.
14.
Mcewan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE diabetes model. Value Health 17(6), 714–724 (2014).
15.
Palmer AJ, Roze S, Valentine WJ et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr. Med. Res. Opin. 20(Suppl. 1), S5–S26 (2004).
16.
Lægemiddelstyrelsen 2018a. Vejledning om udarbejdelse af sundhedsøkonomiske analyser af lægemidler. VEJ nr 9153 af 09/03/2018 (Danish Medicines Agency. Guidelines for the development of health-economic evaluation of medicines) (2018). www.retsinformation.dk/Forms/R0710.aspx?id=199976
17.
Ramos M, Cummings MH, Ustyugova A, Raza SI, De Silva SU, Lamotte M. Long-term cost-effectiveness analyses of empagliflozin versus oral semaglutide, in addition to metformin, for the treatment of Type 2 diabetes in the UK. Diabetes Ther. 11(9), 2041–2055 (2020).
18.
National Institute for Health and Care Excellence (Nice). Type 2 diabetes in adults: management (NICE guideline [NG28]) (2015). www.nice.org.uk/guidance/ng28
19.
Bain SC, Hansen BB, Malkin SJP et al. Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost–effectiveness analyses based on the PIONEER Clinical Trial Programme. Diabetes Ther. 11(1), 259–277 (2020).
•• Provides additional efficacy information.
20.
Lægemiddelstyrelsen 2018b. Vejledning om periodisk revurdering af lægemidlers tilskudsstatus (2018). www.retsinformation.dk/eli/retsinfo/2018/9154
21.
Vive Rapport. En helhjertet indsat - En artikelbaseret klinisk, patientnær og sundhedsøkonomisk kortlægning af hjerte-kar-området, 2018 (VIVE report: a whole-hearted effort – a publication based clinical, patient centric and health economic mapping of the cardiovascular area, 2018) (2018). https://hjerteforeningen.dk/wp-content/uploads/sites/17/2018/02/11162-en-helhjertet-indsats-web.pdf
22.
Beaudet A, Clegg J, Thuresson PO, Lloyd A, Mcewan P. Review of utility values for economic modeling in Type 2 diabetes. Value Health 17(4), 462–470 (2014).
23.
Rind DM, Fazioli K, Borrelli E et al. In: Oral Semaglutide for Type 2 Diabetes: Effectiveness andValue. 4.4 Summary and Comment 7.4 Access and Affordability Alert. Institute for Clinical and Economic Review, MA, USA (2019).
24.
Sundhedsstyrelsen. Farmakologisk glukosesænkende behandling af Type 2-diabetes i almen praksis, Rationel Farmakoterapi nr 10, september 2020 (2020). www.sst.dk/da/Udgivelser/2020/Rationel-Farmakoterapi-10-2020
25.
Rungby J, Schou M, Warrer P, Ytte L, Andersen GS. Prevalence of cardiovascular disease and evaluation of standard of care in Type 2 diabetes: a nationwide study in primary care. Cardiovasc. Endocrinol. 6(4), 145–151 (2017).
26.
Persson F, Bodegard J, Lahtela JT et al. Different patterns of second-line treatment in Type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): a multinational observational study. Endocrinol. Diabetes Metab. 1(4), e00036 (2018).
Information & Authors
Information
Published In
Pages: 29 - 37
PubMed: 34841893
Copyright
© 2021 Niels Ejskjaer. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 15 July 2021
Accepted: 17 September 2021
Published online: 29 November 2021
Keywords:
Topics
Authors
Funding Information
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark. (2021) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2021-0169
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Ian W. Campbell, Kerstin M. G. Brand, Ulrike Gottwald-Hostalek, Julian Dettenbach, Evaluating Cost-Effectiveness in Relation to the Supporting Clinical Evidence Across the Type 2 Diabetes Continuum: A Review of Metformin and SGLT2is, Advances in Therapy, 10.1007/s12325-026-03592-6, (2026).
- Lu Wang, Yinglin Wang, Quan Zhao, Economic evaluation of sodium-glucose transporter 2 inhibitors compared with glucagon-like peptide 1 receptor agonist for the treatment of type 2 diabetes: a systematic review, European Journal of Clinical Pharmacology, 10.1007/s00228-026-04015-9, 82, 4, (2026).
- Mari Pesonen, Virpi Jylhä, Eila Kankaanpää, Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review, JBI Evidence Synthesis, 10.11124/JBIES-23-00511, 22, 11, (2194-2266), (2024).
- Milanne Maria Johanna Galekop, Carin Uyl-de Groot, William Ken Redekop, Economic Evaluation of a Personalized Nutrition Plan Based on Omic Sciences Versus a General Nutrition Plan in Adults with Overweight and Obesity: A Modeling Study Based on Trial Data in Denmark, PharmacoEconomics - Open, 10.1007/s41669-023-00461-8, 8, 2, (313-331), (2023).
- Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard, Lars Holger Ehlers, A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus, PharmacoEconomics, 10.1007/s40273-023-01268-5, 41, 11, (1469-1514), (2023).
- Ryan Pulleyblank, Nikolaj Birk Larsen, Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study, PharmacoEconomics - Open, 10.1007/s41669-023-00416-z, 7, 4, (579-591), (2023).
- E. Biancalana, G. Petralli, F. Raggi, MR. Distaso, G. Piazza, C. Rossi, D. Tricò, A. Solini, Parameters influencing renal response to SGLT2 inhibitors and GLP1 receptor agonists in type 2 diabetes patients with preserved renal function: a comparative, prospective study, Journal of Endocrinological Investigation, 10.1007/s40618-022-01969-2, 46, 5, (991-999), (2022).
- Kristoffer Nilsson, Emelie Andersson, Sofie Persson, Kristina Karlsdotter, Josefin Skogsberg, Staffan Gustavsson, Johan Jendle, Katarina Steen Carlsson, Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease, Diabetes, Obesity and Metabolism, 10.1111/dom.14921, 25, 3, (748-757), (2022).
- Hiroshi BANDO, Useful Oral Administration of Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) as Semaglutide (Rybelsus) for Type 2 Diabetes Mellitus (T2DM), Asploro Journal of Biomedical and Clinical Case Reports, 10.36502/2022/ASJBCCR.6260, 5, 1, (38-41), (2022).
- Samuel J. P. Malkin, Davide Carvalho, Catarina Costa, Vasco Conde, Barnaby Hunt, The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal, Diabetology & Metabolic Syndrome, 10.1186/s13098-022-00801-4, 14, 1, (2022).